Purpose: Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptors (HER) are well-characterized and widely studied breast cancer predictive and prognostic markers that provide important and critical information. The objectives of the current study were to (1) evaluate the trends of ER, PR, and HER tumor markers in breast cancer patients, (2) demonstrate the relationship of ER, PR, and HER status with the age, menopausal status and the site of tumor, (3) evaluate the percentage of HER2 positive patients detected with the Fluorescent in situ hybridization (FISH) technique, and (4) stratify cases according to different molecular subtype classification of breast cancers (ER+PR+HER-, ER+PR-HER1+, ER+PR+HER2+, ER+PR+HER3+, ER-PR+HER1+, ER-PR+HER1+, ER- PR+HER2+ and ER-PR+HER3+).
Methods: The breast cancer subtypes were based on standard Gallen consensus Recommendation (2011). Association between various categorical data was analyzed using Chi-square test followed by Fischer’s exact test. Differences between continuous data were analyzed using student-t test.
Results: A p-value ≤ 0.05 was considered statistically significant. Our study suggests that the incidences of breast cancer were less in the age groups ≤ 40 years (20.6%) and >60 years (18.1%) compared to age groups 41-60 years (56.8%) (p<0.001). We found that younger age group (70 years in western population reported in the literature. While number of ER+ patients in our patient population was 50.0%, number of triple positive patients was15.3%. A high (6.7%) pure PR cases was observed.
Conclusion: In summary, regardless of the hormone status whether it’s single hormone receptor or triple hormone receptor, only age is a variable factor and demonstrates significant difference between HER positive (all the HER2+ cases which are confirmed positive by FISH and HER3+ cases) and negative population. The other two variable factors (menopause and lymph node positivity) are independent of the hormone status.